Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Devon Energy Corp (DVN) vs Novavax Inc (NVAX) Price & Performance

Devon Energy CorpTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Devon Energy Corp vs Novavax Inc — how do they compare? Devon Energy Corp trades at $45.07 (market cap $49.94B), while Novavax Inc trades at $7.94 (market cap $1.31B). The key difference: Devon Energy Corp is far larger — about 38.1× Novavax Inc's market cap, and Devon Energy Corp pays a 2.82% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

DVNNVAX
Market Cap
$49.94B$1.31B
Sector
EnergyHealth
52-Week High
$52.07$11.19
52-Week Low
$31.74$6.22
Enterprise Value
$60.68B$889.30M
Dividend Yield
2.82%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Devon Energy Corp

Devon Energy (DVN) trades at $44.93, down 0.95% on the day, amid a bullish technical signal and strong Q2 2026 earnings that beat estimates. The company reported EPS of $1.57 versus $1.40 expected, driven by merger synergies and higher oil production. Valuation ratios remain attractive with a P/E of 9.87 and EV/EBITDA of 6.89. Recent news highlights a 33% dividend hike and accelerated debt reduction, reinforcing positive sentiment.

The outlook for DVN is positive, supported by robust free cash flow, shareholder returns, and operational execution. Key opportunities include synergy realization from the Coterra merger and a consensus price target of $61.91. Risks involve oil price volatility and integration challenges. Wall Street sentiment is strongly bullish with 71% buy ratings.

Novavax Inc

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Devon Energy Corp

Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.

Read more on DVN

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX